Medicilon (Chuansha) Inc. won the "Development Potential Award" of Chuansha New Town

On March 20, Chuansha New Town grandly held the 2024 Enterprise Commendation Event and Investment Promotion Launching Ceremony.  At the meeting, Medicilon (Chuansha) Inc., a subsidiary of Shanghai Medicilon Inc. (Medicilon), relied on its outstanding performance and strong development momentum in the field of biopharmaceutical, won the "Development Potential Award" for the 2023 Chuansha New Town Economic Work Advanced Unit.

As a one-stop biopharmaceutical preclinical R&D service platform, Medicilon is well-deserved for the award.  Over the past two decades, Medicilon has been deeply involved in the field of biopharmaceutical preclinical research and development.  Medicilon has not only continue to shine in the field of traditional chemical drugs, but also proactively planning ahead in emerging tracks such as bi/multi-specific antibodies, ADCs, PROTACs, mRNA vaccines, small nucleic acid drugs, cells and immunity, and have built a series of efficient and cutting-edge technology service platforms.  By the end of 2023, Medicilon has participated in the research and development of 421 new drugs and generic drug projects that have been approved for clinical use.

Winning the "Development Potential Award" this time is not only an affirmation of Medicilon's own empowerment achievements in the past year, but also recognition of its future development potential.  In the future, Medicilon will continue to take technological innovation as the driving force, keep up with industry development trends, explore more cutting-edge technologies, continue to innovate and improve the R&D service platform, and inject continuous innovative vitality into the vigorous development of the biopharmaceutical industry!